Literature DB >> 10343777

Production of cartilage oligomeric matrix protein (COMP) by cultured human dermal and synovial fibroblasts.

G R Dodge1, D Hawkins, E Boesler, L Sakai, S A Jimenez.   

Abstract

OBJECTIVE: Cartilage oligomeric matrix protein (COMP) is a large disulfide-linked pentameric protein. Each of its five subunits is approximately 100,000 Da in molecular weight. COMP was originally identified and characterized in cartilage and it has been considered a marker of cartilage metabolism because it is currently thought not to be present in other joint tissues, except for tendon. To confirm the tissue specificity of COMP expression we examined cultured human dermal fibroblasts, human foreskin fibroblasts, and normal human synovial cells for the synthesis of COMP in culture.
METHOD: Normal synovial cells and normal human dermal foreskin fibroblasts were isolated from the corresponding tissues by sequential enzymatic digestions and cultured in media containing 10% fetal bovine serum until confluent. During the final 24 h of culture, the cells were labeled with 35S-methionine and 35S-cysteine in serum- and cysteine/methionine-free medium. The newly synthesized COMP molecules were immunoprecipitated from the culture media with a COMP-specific polyclonal antiserum, or with monoclonal antibodies or affinity-purified COMP antibodies. The immunoprecipitated COMP was analyzed by electrophoresis in 5.5% polyacrylamide gels. For other experiments, synovial cells cultured from the synovium of patients with rheumatoid arthritis (RA) and osteoarthritis (OA) were similarly examined.
RESULTS: A comparison of the amounts of COMP produced by each cell type (corrected for the DNA content) revealed that synovial cells produced > or = 9 times more COMP than chondrocytes or dermal fibroblasts. COMP could be easily detected by immunoprecipitation in all cell types. Electrophoretic analysis revealed a distinct band with an apparent MW of 115-120 kDa in samples from each of the three cell types, regardless of the antibody used. COMP expression in cultures of synoviocytes derived from OA and RA patients showed that OA and RA synovial cells produced similar amounts of monomeric COMP of identical size to those COMP monomers produced by normal synovial cells. The addition of TGF-beta to these cultures resulted in an increase in COMP production in normal, OA and RA synovial cells (45, 116 and 115% respectively).
CONCLUSION: These studies demonstrate that substantial amounts of COMP are produced by several mesenchymal cells including synoviocytes and dermal fibroblasts. These findings raise important concerns regarding the utility of measurements of COMP levels in serum or in synovial fluid as markers of articular cartilage degradation because of the likelihood that a substantial proportion of COMP or COMP fragments present in serum or synovial fluid may be produced by cells other than articular chondrocytes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10343777     DOI: 10.1053/joca.1998.0147

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  13 in total

1.  Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis.

Authors:  Kaisa E Happonen; Tore Saxne; Anders Aspberg; Matthias Mörgelin; Dick Heinegård; Anna M Blom
Journal:  Arthritis Rheum       Date:  2010-12

2.  Cartilage oligomeric matrix protein/thrombospondin 5 supports chondrocyte attachment through interaction with integrins.

Authors:  Faye Hui Chen; Ashby O Thomas; Jacqueline T Hecht; Mary B Goldring; Jack Lawler
Journal:  J Biol Chem       Date:  2005-07-28       Impact factor: 5.157

3.  Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials?

Authors:  Joanna Busquets; Francesco Del Galdo; Eugene Y Kissin; Sergio A Jimenez
Journal:  Rheumatology (Oxford)       Date:  2010-03-04       Impact factor: 7.580

4.  Detection of changes in articular cartilage proteoglycan by T(1rho) magnetic resonance imaging.

Authors:  Andrew J Wheaton; George R Dodge; Arijitt Borthakur; J Bruce Kneeland; H Ralph Schumacher; Ravinder Reddy
Journal:  J Orthop Res       Date:  2005-01       Impact factor: 3.494

5.  Body weight independently affects articular cartilage catabolism.

Authors:  W Matt Denning; Jason G Winward; Michael Becker Pardo; J Ty Hopkins; Matthew K Seeley
Journal:  J Sports Sci Med       Date:  2015-05-08       Impact factor: 2.988

6.  Enhancing and maintaining chondrogenesis of synovial fibroblasts by cartilage extracellular matrix protein matrilins.

Authors:  M Pei; J Luo; Q Chen
Journal:  Osteoarthritis Cartilage       Date:  2008-02-20       Impact factor: 6.576

7.  Mutation (D472Y) in the type 3 repeat domain of cartilage oligomeric matrix protein affects its early vesicle trafficking in endoplasmic reticulum and induces apoptosis.

Authors:  Yusuke Hashimoto; Takami Tomiyama; Yoshiki Yamano; Hiroshi Mori
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

8.  Engineering of functional cartilage tissue using stem cells from synovial lining: a preliminary study.

Authors:  Ming Pei; Fan He; Vincent L Kish; Gordana Vunjak-Novakovic
Journal:  Clin Orthop Relat Res       Date:  2008-05-30       Impact factor: 4.176

9.  Elevated Levels of Cartilage Oligomeric Matrix Protein during In Vitro Cartilage Matrix Generation Decrease Collagen Fibril Diameter.

Authors:  Y M Bastiaansen-Jenniskens; A C W de Bart; W Koevoet; K M B Jansen; J A N Verhaar; G J V M van Osch; J DeGroot
Journal:  Cartilage       Date:  2010-07       Impact factor: 4.634

10.  Serum levels of cartilage oligomeric matrix protein are elevated in rheumatoid arthritis, but not in inflammatory rheumatic diseases such as psoriatic arthritis, reactive arthritis, Raynaud's syndrome, scleroderma, systemic lupus erythematosus, vasculitis and Sjögren's syndrome.

Authors:  Martin Skoumal; Günther Haberhauer; Josef Feyertag; Eva Maria Kittl; Kurt Bauer; Attila Dunky
Journal:  Arthritis Res Ther       Date:  2004-03-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.